A new artificial intelligence-driven pipeline developed in a collaborative research combines protein structure prediction, sequence design, and live-cell screening together to enable rapid conversion of antibody sequences into functional intracellular antibodies (intrabodies) that are stable within living cells. By preserving antigen-binding regions and improving structural stability, the approach overcomes major barriers encountered in intrabody development—emerging as a simpler, more cost-effective tool for diagnostics, imaging, and biomedical research.